Science
Our patented TILT® technology, based on oncolytic viral therapies, modifies the tumour microenvironment and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as checkpoint inhibitors and CAR T therapies.
Pipeline
We have multiple best-in-class oncolytic viral therapies. In our pipeline, our lead therapeutic asset, TILT-123, is a cytokine armed oncolytic adenovirus that is currently in clinical trials as monotherapy and in combination with immunotherapies, like immune checkpoint inhibitors or tumor infiltrating lymphocytes (TIL) therapy.
Partners
Our pioneering approach has been recognized by industry leaders including Germany’s Merck KGaA and MSD (a tradename of Merck & Co., Inc.).
